Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Osteitis Deformans × Paclitaxel × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 513 Triple Negative Breast Neoplasms 108 Neoplasm Metastasis 41 Breast Neoplasms, Male 26 Neoplasms 24 Inflammatory Breast Neoplasms 19 Ovarian Neoplasms 18 Carcinoma, Non-Small-Cell Lung 17 Stomach Neoplasms 14 Carcinoma, Ovarian Epithelial 10 Pancreatic Neoplasms 9 Carcinoma, Ductal, Breast 9 Colorectal Neoplasms 8 HER2-positive Breast Cancer 7 Prostatic Neoplasms 6 Parkinson Disease 4, Autosomal Dominant Lewy Body 6 Endometrial Neoplasms 6 Squamous Cell Carcinoma of Head and Neck 5 Melanoma 5 Lung Neoplasms 5 Esophageal Neoplasms 5 Carcinoma, Renal Cell 5 Uterine Cervical Neoplasms 4 Urinary Bladder Neoplasms 4 Anatomic Stage I Breast Cancer AJCC v8 4 Sarcoma 3 Recurrence 3 Peripheral Nervous System Diseases 3 Pathologic Complete Response 3 Lymphoma, Non-Hodgkin 3

Interventions

Lapatinib 2 ribociclib 1 Trastuzumab 1 Paclitaxel 1 Letrozole 1 Goserelin 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00553358 2021-09-21

Neo ALTTO

Novartis

Phase 3 Completed

455 enrolled 34 charts

Breast Neoplasms, Osteitis Deformans

Data powered by HemOnc (CC BY 4.0) Colophon ⚡